ONCIMMUNE HLDNGS
ONCIMMUNE HLDNGS
Share · GB00BYQ94H38 · A2AKAW (XLON)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - 0,00 % -14,20 % -91,81 % -92,06 % -98,98 %

Company Profile for ONCIMMUNE HLDNGS Share

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Company Data

Name ONCIMMUNE HLDNGS
Company Oncimmune Holdings plc
Website https://www.oncimmune.com
Primary Exchange XLON London
WKN A2AKAW
ISIN GB00BYQ94H38
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Martin John Gouldstone
Country United Kingdom
Currency GBP
Employees 0,0 T
Address MediCity, NG90 6BH Nottingham
IPO Date 2016-05-18

Ticker Symbols

Name Symbol
Frankfurt OCY.F
London ONC.L

More Shares

Investors who ONCIMMUNE HLDNGS hold also have the following shares in their portfolio:
PRESSURE TECH.PLC LS -,05
PRESSURE TECH.PLC LS -,05 Share
RTE RE.TRAN.ELE.16-36 MTN
RTE RE.TRAN.ELE.16-36 MTN Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025